(Total Views: 364)
Posted On: 07/22/2019 10:41:39 AM
Post# of 72446
If IPIX was doing the work the payment would be exceptionally more.
Innovation Pharmaceuticals Inc. (the “Company”) entered into an Exclusive License Agreement (the “License Agreement”) with Alfasigma S.p.A., a global pharmaceutical company (“Alfasigma”), granting Alfasigma the worldwide right to develop, manufacture and commercialize locally-administered Brilacidin for the treatment of ulcerative proctitis/ulcerative proctosigmoiditis (UP/UPS).
So the work is on them imo. And thinking they like what they see so far. This is a large market and we'll see our chunk imo.
So it does help relieve a bit of pressure. And the fact that we have our validation, well, I'd say that's the best start of all for n otc.
Innovation Pharmaceuticals Inc. (the “Company”) entered into an Exclusive License Agreement (the “License Agreement”) with Alfasigma S.p.A., a global pharmaceutical company (“Alfasigma”), granting Alfasigma the worldwide right to develop, manufacture and commercialize locally-administered Brilacidin for the treatment of ulcerative proctitis/ulcerative proctosigmoiditis (UP/UPS).
So the work is on them imo. And thinking they like what they see so far. This is a large market and we'll see our chunk imo.
So it does help relieve a bit of pressure. And the fact that we have our validation, well, I'd say that's the best start of all for n otc.
(5)
(0)
